Anzeige
Meldung des Tages: Wall Street. Trump. Antimon - ATMY steht jetzt im Zentrum politischer Macht und kritischer Versorgung

Anixa Biosciences Aktie News

Aktie
WKN:  A2N6ZF ISIN:  US03528H1095 US-Symbol:  ANIX Branche:  Biotechnologie Land:  USA
2,97 $
-0,07 $
-2,30%
2,5154 € 17:21:50 Uhr
Depot/Watchlist
Marktkapitalisierung *
87,53 Mio. €
Streubesitz
77,91%
KGV
-11,80
Index-Zuordnung
-

Anixa Biosciences News

08.09.25 - PR Newswire
Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival
Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival PR ...
02.09.25 - PR Newswire
Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference PR Newswire
25.08.25 - PR Newswire
Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference PR Newswire
20.08.25 - IRW-Press
Anixa Biosciences erhält von der Chinese National Intellectual Property Administration eine Patentbewilligung für seine Brustkrebsimpfstoff-Technologie
Mit dem Zulassungsbescheid erhält Anixa das erste chinesische Patent für seinen Brustkrebsimpfstoff Der globale Schutz des geistigen Eigentums wird auf Märkte mit hoher ...
20.08.25 - PR Newswire
Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology PR Newswire
18.08.25 - PR Newswire
Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial PR Newswire
12.08.25 - PR Newswire
Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology
Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology PR Newswire
08.08.25 - PR Newswire
Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference
Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference PR Newswire
04.08.25 - PR Newswire
Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial
Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial PR Newswire
30.07.25 - PR Newswire
Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology PR Newswire
24.07.25 - PR Newswire
Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s
Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s PR Newswire
09.07.25 - IRW-Press
Anixa Biosciences meldet Erteilung eines weiteren US-Patents für die Impfstofftechnologie gegen Eierstockkrebs
SAN JOSE, Kalifornien, 9. Juli 2025 / IRW-Press / Anixa Biosciences, Inc. (Anixa oder das Unternehmen) (NASDAQ: ANIX), ein auf die Krebstherapie und Krebsprävention ...
09.07.25 - PR Newswire
Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology
Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology PR Newswire
23.06.25 - IRW-Press
Anixa Biosciences beginnt mit Verabreichung an die vierte Kohorte im Rahmen der klinischen Studie zur CAR-T-Therapie beim Ovarialkarzinom
Die Dosis der vierten Kohorte beträgt drei Millionen CAR-​positive Zellen - dreißigmal höher als die Dosis der ersten Kohorte SAN JOSE, Kalifornien, 23. Juni 2025 / IRW-Press / ...
23.06.25 - PR Newswire
Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial PR Newswire
20.06.25 - IRW-Press
Anixa Biosciences veranstaltet am 26. Juni 2025 einen Webcast für Investoren
SAN JOSE, Kalifornien, 20. Juni 2025 / IRW-Press / Anixa Biosciences, Inc. (Anixa oder das Unternehmen) (NASDAQ: ANIX), ein auf die Krebstherapie und Krebsprävention ...
20.06.25 - PR Newswire
Anixa Biosciences to Host an Investor Webcast on June 26, 2025
Anixa Biosciences to Host an Investor Webcast on June 26, 2025 PR Newswire
12.06.25 - PR Newswire
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry PR Newswire
12.06.25 - PR Newswire
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry PR Newswire
10.06.25 - PR Newswire
Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage
Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage PR Newswire

Newssuche

Videos

newspaper
12:40 Uhr +27,72%
Technical Trading Silber Crash!
Silber Short Typ: Turbo Open End WKN: VJ4GQU Hebel: 3,77 Laufzeit: OpenEnd Einstieg: Market ... Mehr »